No evidence for XMRV association in pediatric idiopathic diseases in France. by Jeziorski, Eric et al.
No evidence for XMRV association in pediatric
idiopathic diseases in France.
Eric Jeziorski, Vincent Foulongne, Catherine Ludwig, Djamel Louhaem, Gilles
Chiocchia, Michel Segondy, Michel Rodie`re, Marc Sitbon, Vale´rie Courgnaud
To cite this version:
Eric Jeziorski, Vincent Foulongne, Catherine Ludwig, Djamel Louhaem, Gilles Chiocchia, et al..
No evidence for XMRV association in pediatric idiopathic diseases in France.. Retrovirology,
BioMed Central, 2010, 7 (1), pp.63. <10.1186/1742-4690-7-63>. <inserm-00617228>
HAL Id: inserm-00617228
http://www.hal.inserm.fr/inserm-00617228
Submitted on 26 Aug 2011
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
SHORT REPORT Open Access
No evidence for XMRV association in pediatric
idiopathic diseases in France
Eric Jeziorski1,2, Vincent Foulongne3, Catherine Ludwig2, Djamel Louhaem4, Gilles Chiocchia5, Michel Segondy3,
Michel Rodière2, Marc Sitbon1, Valérie Courgnaud1*
Abstract
Retroviruses have been linked to a variety of diseases such as neoplastic and immunodeficiency disorders and neu-
rologic and respiratory diseases. Recently, a novel infectious human retrovirus, the xenotropic murine leukemia
virus-related virus (XMRV), has been identified in cohorts of patients with either a familial type of prostate cancer or
chronic fatigue syndrome. The apparent unrelatedness of these diseases raised the question of the potential invol-
vement of XMRV in other diseases.
Here, we investigated the presence of XMRV in a selection of pediatric idiopathic infectious diseases with symp-
toms that are suggestive of a retroviral infection, as well as in children with respiratory diseases and in adult
patients with spondyloarthritis (SpA). Using a XMRV env-nested PCR, we screened 72 DNA samples obtained from
62 children hospitalized in the Montpellier university hospital (France) for hematological, neurological or inflamma-
tory pathologies, 80 DNA samples from nasopharyngeal aspirates from children with respiratory diseases and 19
DNA samples from SpA. None of the samples tested was positive for XMRV or MLV-like env sequences, indicating
that XMRV is not involved in these pathologies.
Findings
Retroviruses have been isolated from a wide variety of
animal species and have been linked to a broad range of
diseases, including neoplasia, non-neoplastic hematologi-
cal or inflammatory diseases, immunodeficiencies and
neurodegenerative and respiratory syndromes [1-3].
However in humans, it was not until the early 1980 s
that two pathogenic retroviruses were isolated, a deltare-
trovirus, the human T cell leukemia virus (HTLV), and
a lentivirus, the human immunodeficiency virus (HIV).
Both HTLV and HIV appear to have resulted from
cross-species transmissions from non-human African
primates involving simian T-cell leukemia viruses
(STLV) and simian immunodeficiency viruses (SIV),
respectively [4,5]. Interestingly, two new types of HTLV,
HTLV-3 and 4 have recently been reported [6-8]. Cross-
species transmission of gammaretroviruses amongst ver-
tebrates has also been established. For example, the
avian spleen necrosis virus (SNV) derives from a murine
leukemia virus (MLV) and a koala endogenous retro-
virus (KoRV) have been shown to be related to the gib-
bon ape leukemia retrovirus [9]. In 2006, an infectious
human gammaretrovirus was found in prostate tissue
samples from cancer patients [10]. Phylogenetic analyses
revealed that this virus was closely related to several
known xenotropic mouse leukemia viruses (xeno-MLV),
and thus was coined XMRV for xenotropic murine leu-
kemia virus-related virus. XMRV displays more than
90% sequence identity with MLV and harbors distinct
amino acid substitutions and a short deletion in the gag
leader region. Strikingly, these combined features lead to
a putative absence of glycoGag, an alternative open
reading frame of the gag gene that has been shown to
play a role in MLV replication and pathogenesis [11].
The cellular receptor for XMRV has been shown to be
the same as for xeno-MLV, i.e. XPR1 [12], a multipass
membrane protein with unknown function [13]. XMRV
was first described in patients who develop a familial
form of prostate cancer associated with RNAse L defi-
ciency [10]. However, in subsequent studies, a preva-
lence of 23% of XMRV infection in prostate cancer
patients has been reported to be independent of the
RNase L gene mutation [14]. More recently, XMRV has
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also been found, with a high prevalence, in the blood of
patients with chronic fatigue syndrome (CFS), unveiling
a potential broader prevalence of XMRV [15]. Most sur-
prisingly, the prostate cancer and CFS XMRV isolates
are almost identical with over 98% nucleotide sequence
identity. This homology suggests that XMRV has
recently arisen from a common ancestor, and that the
number of replication cycles that took place during
transmission and/or within one infected individual is
limited.
The association of XMRV with these two pathologies
remains debated in part due to the fact that several stu-
dies by European teams and a more recent one in the
United States did not detect XMRV by PCR in either
types of patients [16-22]. When detected, XMRV preva-
lence in the United States appears to be up to 40% and
67% in prostate cancer patients and CFS patients,
respectively, while in Northern Europe, the prevalence is
virtually zero. Furthermore, Lombardi et al., found a 4%
prevalence of XMRV in control patients from the same
geographic region [15]. In view of the striking conserva-
tion of XMRV sequences, the lack of detection of
XMRV is unlikely due to potential differences in PCR
sensitivity. Therefore, differences in the worldwide dis-
tribution of XMRV may rather result from an infection
that would have recently occurred in North America
and that is not yet widespread in other parts of the
world, or at least in Western Europe.
Retroviral pathogenesis most frequently involves
hematopoietic, neurological and/or vascular symptoms
through lytic, inflammatory or proliferative processes.
In many human diseases of unknown etiology, retro-
viral involvement has recurrently been suspected. Since
XMRV has been reported to be present in very differ-
ent clinical entities and to a lesser extent in control
samples, we wished to address the potential presence
of XMRV in France, outside of CFS and prostate
cancer.
While cross-species transmission is likely to take place
during predatory interactions involving blood exchange,
intraspecies spreading is most likely to occur through
sexual exchanges or from mother-to-infant. Very few
studies have been performed in pediatric samples to
monitor potential retrovirus infection others than those
with HIV and HTLV. In this study, we wanted to inves-
tigate XMRV as a possible etiologic agent for a selection
of pediatric idiopathic diseases suggestive of retroviral
infection.
Blood samples or synovial fluid cells were collected
from pediatric patients less than 17 years of age
admitted at the University Hospital of Montpellier
(CHU Montpellier). This ongoing collection of pedia-
trics samples of idiopathic infectious diseases was
started on September 2007, in accordance to the ethical
guidelines of the French Ministry of Health (DC-2009-
1052). All patients or their legal representatives have
given their written informed consent.
Blood samples were drawn by venipuncture using
standard phlebotomy procedures into 2 ml sterile
microtubes containing EDTA, and synovial fluids were
obtained by needle puncture and transferred in special
collection tubes. For each samples, at least 2 aliquots
were prepared and stored at -80°C for later use. Total
DNA was isolated from whole blood or synovial fluid
cells using the QIAamp blood kit (Qiagen, Courtaboeuf,
France) according to the manufacturer’s instructions.
DNA concentrations were determined by Nanodrop
ND-1000 spectrophotometer. To ensure quality of the
DNA extracts, all samples were subjected to a single-
round PCR reaction using GAPDH primers (Figure 1A).
Bacterial exploration with direct examination and cul-
ture was performed in all synovial fluid samples with no
bacterial agent found.
The present study included 72 samples obtained from
62 children who exhibited hematological, neurological
or inflammatory pathologies. All pathologies selected
are listed in Table 1. In addition, we screened 80 ran-
dom nasopharyngeal aspirates collected from a cohort
of children aged < 5 years with respiratory diseases
(including mostly bronchiolitis, >90%, pneumonia and
asthma) [23].
We also screened samples from 19 adult patients with
spondyloarthritis (SpA), a chronic inflammatory disorder
resembling the juvenile idiopathic arthritis, our largest
cohort of pediatric patients. The SpA samples were pre-
viously tested for the presence of HTLV-related
sequences using a sensitive semi-nested DNA amplifica-
tion method allowing the detection of all PTLV-like
sequences [24]. No HTLV-like sequences were found in
SpA patients (unpublished data).
We designed primers to specifically target XMRV-like
sequences. A 600-bp region of the SU env gene, span-
ning the receptor binding domain (RBD) was amplified
with the following primers with positions indicated
according to the XMRV VP35 sequence [10]: XenvS1:
5′-ATGGAAAGTCCAGCGTTCTCAAA-3′ (5754 to
5776) and XenvAS1: 5′-ATGGGGACGCGGGGCCCTA-
CATTG-3′ (6443 to 6466) for the first round, while
primers for the second round were XenvS2: 5′;-
AGGAGCCTCGGTACAACGTGACAG-3 (5840 to
5863), and XenvAS2: 5′-TGGCGGGTCAGAGAGAA-
CAGGG-3′ (6415 to 6437).
Specificity of the primers was verified in silico http://
www4a.biotec.or.th/cgi-bin/webPcr and confirmed
experimentally by PCR amplification on random human
DNA isolated from peripheral blood mononuclear cells
(PBMCs). The sensitivity of our XMRV PCR was esti-
mated with 10-fold serial dilutions of a plasmid
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containing the env gene (kind gift from N. Fischer) in
the presence of 500 ng of human PBMC DNA. In our
PCR conditions, a threshold sensitivity of 10 copies per
reaction was consistently achieved (Figure 1B).
Between 300 ng and 500 ng of DNA for each sample
were assayed by nested PCR. PCR was performed for
both rounds with High Fidelity Platinum® Taq DNA
Polymerase (Invitrogen), including a hot start (94°C for
2 min) with the following cycle conditions: 38 cycles of
denaturation at 94°C for 20 s, annealing at 54°C for
30 s, and extension at 72°C for 1 min with a final elon-
gation step at 72°C for 10 min before cooling to 4°C.
None of the 152 pediatric samples (72 various idio-
pathic diseases and 80 respiratory diseases) and the 19
SpA samples tested was positive for XMRV (Figure 1C)
or related env sequence, since our primers also allowed
Table 1 List of samples from pediatric patients
Pediatric Pathology Age range* Number of patients Sample origin
Idiopathic thrombocytopenic purpura 11 m -16 y 9 7 Whole blood
1 Bone marrow
1 Whole blood - Bone marrow
Autoimmune hemolytic anemia 4 y - 16 y 3 2 Whole blood
1 Whole blood - Bone marrow
Aregenerative anemia 1.5 y -8 y 3 1 Whole blood
1 Bone marrow
1 serum
Idiopathic aplasia 12 y 1 Whole blood
Neutropenia 1 m - 3 y 4 3 Whole blood
1 Bone marrow
Juvenile idiopathic arthritis 2 y -16 y 34 5 Whole blood
21 Synovial fluid cells
8 Whole blood - Synovial fluid cells
Henoch-Schönlein syndrome 6 y- 6 y 2 Whole blood
Encephalitis 3 y - 9 y 3 Whole blood
Dermatomyositis 9 y 1 Whole blood
Leucosis 1.5 y -15 y 2 Whole blood
* m = month, y = year
A
C
13 151 3 42 1095 6 7 118 12 14 16
+
-
M
-
B
10 6  10 5   10 4  10 3  10 2  10   1   0M
600bp
210bp
Figure 1 Results of XMRV env nested PCR. (A) GAPDH PCR on the DNA of 16 out of the 72 pediatric idiopathic diseases samples. Lanes 1-12
= DNA extracted from whole blood. Lanes 13-16 = DNA extracted from synovial fluid cells. (B) Sensitivity of the XMRV env PCR. Dilution series
of 106 to 1 copies of a XMRV plasmid DNA in human genomic DNA. The limit of detection in our assay was 10 copies. (C) Nested PCR with
XMRV env primers of the samples shown in A. Lane M, 100 bp marker; lane +, 600 bp PCR positive control from a XMRV env-containing plasmid;
Lane-, PCR water control.
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us to detect both xeno-MLV and polytropic MLV
[25,26].
In contrast with our results on pediatrics respiratory
disease samples (bronchiolitis and others), Fischer et al.
found a significant proportion of XMRV gag sequences
in all of their respiratory disease patient and donor
groups (between 2 to 10%). They found the highest inci-
dence of gag XMRV detection in the group of immuno-
suppressed patients (adults conditioned before
transplant) [27]. Although, this confirms that XMRV is
more likely to emerge in the context of altered immune
response, it remains perplexing that no other report
found XMRV in Europe.
We showed that our nested PCR procedure is sensi-
tive enough to detect as few as 10 copies of an XMRV
env gene in a sample. Moreover, we have shown that we
were able to detect XMRV-related env sequences such
as xeno-MLV and the related polytropic MLV. However,
we cannot formally exclude that variant viruses lacking
the env sequences that match our primers would be pre-
sent in some of these samples. Nevertheless, the remark-
able conservation of XMRV env sequences described in
all the studies published so far rather argues in favor of
a bona fide absence of XMRV infection in these pathol-
ogies. Furthermore, a representative third of our samples
was also unsucessfully amplified with XMRV gag specific
primers (not shown).
As mentioned above, gammaretroviruses also partici-
pate in zoonotic transmissions [28]. Therefore, the
absence of XMRV in pediatric patients as described here
should not discourage the search for other gammaretro-
viruses potentially able to cross the species barrier
through recognition of human receptors by their envel-
ope glycoproteins.
Abbreviations
ENV: envelope glycoprotein; GAPDH: Glyceraldehyde 3-phosphate
dehydrogenase; PCR: Polymerase Chain Reaction; PTLV: Primate T-cell
lymphotropic virus; SU: Env extracellular surface component.
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